Solberg Asia Pacific
Product Toxicity Summary Sheet

Product Name	**Solberg Rehealing Foam™ RF6 Firefighting Foam Concentrate (6%)**	Issue Date	Oct. 24, 2007
		Supersedes	None

Below is a summary of the study giving an indication of the relative toxicity of the product. (Definition of test procedures are found on the reserve side of the sheet.) This summary is the data for the precautionary use information with the product.
Relative toxicity of a material is only one factor that is important in determining the degree of hazard in handling a chemical or product. Other considerations to include are physical properties of the chemical, extent and frequency of use or exposure, intended use, and possible misuse of the product. For additional information regarding safe handling of the product, please reference the Material or Product Safety Data Sheet.

SINGLE DOSE ORAL TOXICITY IN RATS:
Five health male and five healthy female Wistar albino rats were dosed orally with RF6 Foam at 2000mg/kg of body weight. The animals were observed twice daily for mortality. Body weights were recorded immediately pre-test, weekly and at termination. All animals were examined for gross pathology.

All animals survived the 2000 mg/kg oral dose.

Body weight changes were normal in 9/10 animals. Animal (#3) lost weight by day 4, but gained by day 14.

Necropsy results were normal.

The oral LD50 of RF6 Foam is greater than 2000 mg/kg.
(MB Research Laboratories; Aug 02, 2002; MB 02-10197.01)

ACUTE EYE IRRITATION IN RABBITS:
Three healthy New Zealand rabbits (male), free from evidence of ocular irritation and corneal abnormalities, were dosed with RF6 Foam. The test article (0.1mg) was placed into the conjunctival sac of one eye of each rabbit. The eyes were examined and scored by the Draize technique at 1, 24, 48 and 72 hours and again on days 7 and 14. The primary eye irritation score for each rabbit, each day, was calculated.

Corneal opacity, noted in 1/3 eyes, cleared by 48 hours. Fluorescein stain retention was noted in all 3 eyes and cleared by 72 hours. Iritis, noted in 3/3 eyes, cleared by 48 hours. Conjunctival irritation, noted in 3/3 eyes, cleared by day 14.

There were no abnormal physical signs noted during any observation period.

Ocular administration of RF6 Foam produced corneal opacity and irritation which cleared within 14 days.

This material is considered to be moderately irritating to the eye.
(MB Research Laboratories; Aug 02, 2002; MB 02-10197.04)

Solberg Asia Pacific
Product Toxicity Summary Sheet

Product Name	**Solberg Rehealing Foam™ RF6 Firefighting Foam Concentrate (6%)**	Issue Date	Oct. 24, 2007
		Supersedes	None

Below is a summary of the study giving an indication of the relative toxicity of the product. (Definition of test procedures are found on the reserve side of the sheet.) This summary is the data for the precautionary use information with the product.
Relative toxicity of a material is only one factor that is important in determining the degree of hazard in handling a chemical or product. Other considerations to include are physical properties of the chemical, extent and frequency of use or exposure, intended use, and possible misuse of the product. For additional information regarding safe handling of the product, please reference the Material or Product Safety Data Sheet.

ACUTE PRIMARY DERMAL IRRITATION IN RABBITS:
Six healthy New Zealand White rabbits were dosed dermally with RF6 Foam. The test article (0.5ml) was applied to one intact and one abraded site on the clipped back of each rabbit for a total dose of 1.0mg/rabbit. The sites were occluded for 24 hours. Skin reactions were evaluated by the Draize technique at 24 and 72 hours after dosing. The Primary Irritation Index was calculated. Body weights were recorded pre-test.

Erythema and edema were barely perceptible to well defined at 24 hours post dose and absent to well defined at 72 hours.

There were no abnormal physical signs noted during the observation period.

RF6 Foam is not a dermal irritant as defined in 16 CFR 1500.41 and 16 CFR 1500.3 (c) (4).
(MB Research Laboratories; Aug 01, 2002; MB 02-10197.03)